BioSpace News Archive

Sol-Millennium Inc., a medical device company and innovator in medication delivery and specimen collection, announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Sol-Guard® Safety Pull Button Blood Collection Set, the newest safety device in the company’s rapidly expanding blood collection portfolio.

Kinaxis today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2022.

Matinas BioPharma Holdings, Inc. today announced that the Infectious Diseases Society of America (IDSA), one of the four sponsoring societies for IDWeek 2022.

Nephros, Inc. today announced that it will file its third-quarter financial results on Wednesday, November 2, 2022 after market close and will host a conference call that same day at 4:30 pm ET.

Ocugen, Inc. today announced that it will host an in-person Research & Development (R&D) Day on Tuesday, November 1, 2022.

Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII and DYANAVEL® XR.

Sinaptica Therapeutics, Inc today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s investigational SinaptiStim™ – AD System for the treatment of cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD).

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced that it will report results for third quarter ended September 30, 2022, and provide an update on recent developments in its business after market close on Tuesday, November 1, 2022.

Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have three poster presentations at the 2022 Society for Immunotherapy for Cancer 37th Annual Meeting.